[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condbio:acute-lymphoblastic-leukemia:bcr-abl1-fusion-gene":3},{"condition":4,"biomarker":5,"total":6,"trials":7},"Acute Lymphoblastic Leukemia","BCR\u002FABL1 Fusion Gene",15,[8,16,23,30,36,43,50,56,62,68,74,80,86,92,98],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT04747912","Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO)",[12],"Phase 2","RECRUITING","2026-08-26T02:18:33.598205Z","2026-06-06T00:48:49.516454Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT06051409","A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)",[20],"Phase 3","2026-08-26T02:18:29.369233Z","2026-05-13T02:55:06.404671Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":28,"content_modified":29},"NCT06308588","Phase I\u002FII Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia",[27],"Phase 1\u002FPhase 2","2026-08-26T02:16:17.877565Z","2026-05-05T02:43:29.682278Z",{"nct_id":31,"title":32,"phases":33,"status":13,"updated_at":34,"content_modified":35},"NCT03263572","Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed\u002FRefractory, Acute Lymphoblastic Leukemia",[12],"2026-08-26T02:16:08.402952Z","2026-05-05T02:43:28.640935Z",{"nct_id":37,"title":38,"phases":39,"status":13,"updated_at":41,"content_modified":42},"NCT04877522","Asciminib Roll-over Study",[40],"Phase 4","2026-08-26T02:19:28.327680Z","2026-05-05T02:43:27.182842Z",{"nct_id":44,"title":45,"phases":46,"status":13,"updated_at":48,"content_modified":49},"NCT05535855","UCD19 CAR T Therapy in Adults With B-ALL and MRD Positivity in CR1",[47],"Phase 1","2026-08-26T02:16:03.788292Z","2026-05-05T02:35:31.898196Z",{"nct_id":51,"title":52,"phases":53,"status":13,"updated_at":54,"content_modified":55},"NCT06315309","Trial of 2 Step ATG for Acute GVHD Prevention Post Myeloablative Allogeneic Stem Cell Transplant",[12],"2026-08-26T02:16:48.735701Z","2026-05-05T02:43:29.662218Z",{"nct_id":57,"title":58,"phases":59,"status":13,"updated_at":60,"content_modified":61},"NCT02727803","Personalized NK Cell Therapy in CBT",[12],"2026-08-26T02:18:36.226508Z","2026-05-05T02:43:29.030294Z",{"nct_id":63,"title":64,"phases":65,"status":13,"updated_at":66,"content_modified":67},"NCT04099966","AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha\u002FBeta T Cell and CD19+ B Cell Depletion",[12],"2026-08-26T02:19:24.527214Z","2026-05-05T02:43:28.713058Z",{"nct_id":69,"title":70,"phases":71,"status":13,"updated_at":72,"content_modified":73},"NCT05857969","Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling",[47],"2026-08-26T02:18:00.873391Z","2026-05-05T02:43:28.220097Z",{"nct_id":75,"title":76,"phases":77,"status":13,"updated_at":78,"content_modified":79},"NCT05805605","Allo HSCT Using RIC and PTCy for Hematological Diseases",[12],"2026-08-26T02:17:29.353236Z","2026-05-05T02:43:28.075410Z",{"nct_id":81,"title":82,"phases":83,"status":13,"updated_at":84,"content_modified":85},"NCT03630991","Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy",[47],"2026-08-26T02:18:41.390601Z","2026-05-05T02:43:27.485890Z",{"nct_id":87,"title":88,"phases":89,"status":13,"updated_at":90,"content_modified":91},"NCT04195633","Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies",[12],"2026-08-26T02:17:07.954622Z","2026-05-05T02:43:27.479357Z",{"nct_id":93,"title":94,"phases":95,"status":13,"updated_at":96,"content_modified":97},"NCT03016806","Umbilical Cord Blood Transplantation From Unrelated Donors",[],"2026-08-26T02:15:21.365312Z","2026-05-13T02:55:06.119599Z",{"nct_id":99,"title":100,"phases":101,"status":102,"updated_at":103,"content_modified":104},"NCT02646839","KIR Favorable Mismatched Haplo Transplant and KIR Polymorphism in ALL\u002FAML\u002FMDS Allo-HCT Children",[12],"ENROLLING_BY_INVITATION","2026-08-26T02:17:30.961790Z","2026-06-16T05:54:07.966507Z"]